258 related articles for article (PubMed ID: 33724679)
21. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
Jandova J; Wondrak GT
J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
Koetz-Ploch L; Hanniford D; Dolgalev I; Sokolova E; Zhong J; Díaz-Martínez M; Bernstein E; Darvishian F; Flaherty KT; Chapman PB; Tawbi H; Hernando E
Pigment Cell Melanoma Res; 2017 May; 30(3):328-338. PubMed ID: 28140520
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
[TBL] [Abstract][Full Text] [Related]
24. Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen.
Goh CJH; Wong JH; El Farran C; Tan BX; Coffill CR; Loh YH; Lane D; Arumugam P
G3 (Bethesda); 2021 Feb; 11(2):. PubMed ID: 33604667
[TBL] [Abstract][Full Text] [Related]
25. Enhanced expression of p21 promotes sensitivity of melanoma cells towards targeted therapies.
Fröhlich LM; Makino E; Sinnberg T; Schittek B
Exp Dermatol; 2022 Aug; 31(8):1243-1252. PubMed ID: 35514255
[TBL] [Abstract][Full Text] [Related]
26. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
27. Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors.
Ruffini F; Ceci C; Atzori MG; Caporali S; Levati L; Bonmassar L; Cappellini GCA; D'Atri S; Graziani G; Lacal PM
Pharmacol Res; 2023 Jun; 192():106782. PubMed ID: 37127213
[TBL] [Abstract][Full Text] [Related]
28. Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.
Feddersen CR; Schillo JL; Varzavand A; Vaughn HR; Wadsworth LS; Voigt AP; Zhu EY; Jennings BM; Mullen SA; Bobera J; Riordan JD; Stipp CS; Dupuy AJ
Cancer Res; 2019 Oct; 79(19):5074-5087. PubMed ID: 31416844
[TBL] [Abstract][Full Text] [Related]
29. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
30. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
31. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
[TBL] [Abstract][Full Text] [Related]
32. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
[TBL] [Abstract][Full Text] [Related]
33. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
34. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
[TBL] [Abstract][Full Text] [Related]
35. Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.
Li B; Kong X; Post H; Raaijmakers L; Peeper DS; Altelaar M
J Proteome Res; 2021 Sep; 20(9):4381-4392. PubMed ID: 34343000
[TBL] [Abstract][Full Text] [Related]
36. AXL inhibition improves BRAF-targeted treatment in melanoma.
Nyakas M; Fleten KG; Haugen MH; Engedal N; Sveen C; Farstad IN; Flørenes VA; Prasmickaite L; Mælandsmo GM; Seip K
Sci Rep; 2022 Mar; 12(1):5076. PubMed ID: 35332208
[TBL] [Abstract][Full Text] [Related]
37. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
[TBL] [Abstract][Full Text] [Related]
38. Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Fragale A; Stellacci E; Romagnoli G; Licursi V; Parlato S; Canini I; Remedi G; Buoncervello M; Matarrese P; Pedace L; Ascione B; Pizzi S; Tartaglia M; D'Atri S; Presutti C; Capone I; Gabriele L
Int J Cancer; 2023 Sep; 153(5):1080-1095. PubMed ID: 37293858
[TBL] [Abstract][Full Text] [Related]
39. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.
Li YY; Wu C; Chen SM; Shah SS; Wangpaichitr M; Feun LG; Kuo MT; Suarez M; Prince J; Savaraj N
Oncotarget; 2016 Apr; 7(14):17665-80. PubMed ID: 26771234
[TBL] [Abstract][Full Text] [Related]
40. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
Tian Y; Guo W
Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
